Should You Buy Aspira Women's Health Inc (AWH) Stock on Thursday?

The market has been down on Aspira Women's Health Inc (AWH) stock recently. AWH gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Aspira Women's Health Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on AWH!

See Full AWH Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With AWH Stock Today?

Aspira Women's Health Inc (AWH) stock has fallen -6.52% while the S&P 500 is up 0.05% as of 12:50 PM on Thursday, Mar 28. AWH is down -$0.23 from the previous closing price of $3.45 on volume of 7,802 shares. Over the past year the S&P 500 has gained 32.23% while AWH is down -41.80%. AWH lost -$1.99 per share in the over the last 12 months. To screen for more stocks like Aspira Women's Health Inc click here.

More About Aspira Women's Health Inc

Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. Click Here to get the full Stock Report for Aspira Women's Health Inc stock.